Investors


Introduction


Helix BioPharma's product development initiatives include its novel L-DOS47 new drug product candidate for the treatment of inoperable, locally, advanced, recurrent, or metastatic non-small cell lung cancer and pancreatic cancer. For more information contact Investor Relation or Shareholder Services.

FINANCIAL INFORMATIONLATEST ANNUAL REPORTLATEST QUARTERLY REPORTCORPORATE PRESENTATIONSEDAR

Latest news

All News

Latest presentations

All Presentations